NCT00819728已完成2 期
Multicenter Phase II Trial of Weekly Taxotere and Irinotecan (CPT-11) in Patients With Advanced Non-small Cell Lung Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Sanofi
- 入组人数
- 35
- 试验地点
- 1
研究概览
简要总结
The main purpose of the study is to determine the activity of the weekly combination of docetaxel (Taxotere) and irinotecan in terms of response rate in subjects with advanced, previously untreated, non-small cell lung cancer. It is also to determine the activity of this combination in terms of response duration, time to progression, median survival, overall survival, and percent one-year survival, as well as the side-effect and toxicity profile of weekly Taxotere and weekly irinotecan.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Microscopically or cytologically confirmed non-small cell lung cancer. Histology may include large cell, squamous cell, undifferentiated, or bronchioalveolar carcinoma, or adenocarcinoma, but no small cell or carcinoid.
- •Inoperable stage III B or metastatic stage IV NSCLC
- •Measurable (bidimensionally) indicator lesion(s) which have not been irradiated.
- •No prior systemic chemotherapy. Prior irradiation for NSCLC is permitted, however, the measurable or evaluable non-measurable disease must be completely outside the radiation portal or there must be radiologic proof of progressive disease. If a patient is receiving palliative radiation, other than the chest, to one site at 30 cGy or less, then the patient is eligible and chemotherapy can proceed immediately after palliative RT.
- •ECOG performance status 0 or 1 at screening and on the first day of treatment
- •Life expectancy = 12 weeks.
- •Patients must be > 4 weeks from prior radiation therapy to the pelvis, spine or long bones, and must be recovered from all side effects.
- •Patients must be > 3 weeks from prior major surgery, except for a simple biopsy or placement of a venous access device.
排除标准
- •No patient may have the following:
- •Neutrophils < 1,500/mm
- •Platelets < 100,000/mm
- •Serum creatinine >1.8 mg/dL.
- •SGOT > 1.5 times the upper limit of normal for institution.
- •Total bilirubin > the upper limit of normal for institution.
- •Alkaline phosphatase > 5 times the upper limit of normal for institution.
- •Pregnant or lactating females or females of childbearing potential not employing adequate contraception.
- •History of other malignancy within the last five years which could affect the diagnosis of NSCLC, except basal cell carcinoma of the skin or carcinoma in situ of the cervix.
- •Current metastatic CNS disease, if present, must have been treated and clinically stable for at least 3 weeks prior to initial Taxotere treatment. Patients with documented meningeal carcinomatosis are not eligible.
- •Grade 2 or greater peripheral neuropathy.
- •Psychological, familial, sociological or geographical conditions which do not permit weekly medical follow-up and compliance with the study protocol.
- •Patients who are medically unstable, including but not limited to active infection, acute hepatitis, gastrointestinal bleeding, uncontrolled cardiac arrhythmias, uncontrolled angina, uncontrolled hypercalcemia, uncompensated congestive heart failure, uncontrolled diabetes, dementia, seizures, superior vena cava syndrome, and patients whose circumstances do not permit completion of the study or the required follow-up.
- •Patients with a history of hypersensitivity reaction to products containing Polysorbate 80 (Tween 80).
- •Patients requiring concurrent treatment with corticosteroids unless chronic treatment (> 6 months) at low doses (< 20 mg/day of methylprednisolone or equivalent).
- •Patients receiving an investigational drug within 3 weeks of registration.
- •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
研究组 & 干预措施
Taxotere/Irinotecan
Experimental
干预措施: Docetaxel (Drug)
Taxotere/Irinotecan
Experimental
干预措施: Irinotecan (Drug)
研究者
研究点 (1)
Loading locations...
相似试验
终止
2 期
A Study of Docetaxel in Combination With Capecitabine in Stomach and Esophagus CancersCancerNCT00177255University of Pittsburgh40
已完成
2 期
Docetaxel, Cisplatin, and S-1 (TPS) Induction Chemotherapy in Locally Advanced Head and Neck CancerHead and Neck CancerNCT01645748Chonnam National University Hospital35
已完成
2 期
A Study of Weekly Taxotere and Xeloda in Metastatic Breast CancerMetastatic Breast CancerNCT00214864Cancer Research Network18
已完成
2 期
A Study of a New Combination and Schedule of Chemotherapy Drugs for the Treatment of Head and Neck CancerHead and Neck CancerNCT00148122University of Michigan Rogel Cancer Center40
已完成
2 期
Weekly Docetaxel and Four Weekly Carboplatin in Non-small Cell Lung Cancer Carbo-TaxLung NeoplasmsNCT00826852Sanofi49